Seizure freedom · people with epilepsy
It is very uncertain whether rapid changes seizure freedom after 1 year of AED withdrawal compared with slow withdrawal of antiepileptic drugs (very low certainty).
3 findings from 1 review
RR 0.76 [0.58, 1.01]
1 study · 149 participants
Very low
RR 0.87 [0.58, 1.29]
1 study · 149 participants
Very low
RR 1.4 [0.54, 3.65]
1 study · 149 participants
Very low
Completion of withdrawal treatment − Outpatient · Adults or adolescents with opioid dependence
It is very uncertain whether rapid changes completion of withdrawal treatment − Outpatient compared with slow taper of buprenorphine dose (very low certainty).
1 finding from 1 review
Abstinents at · Adults or adolescents with opioid dependence
Rapid showed no clear difference in number abstinent at completion of dose taper − Inpatient compared with slow taper of buprenorphine dose (low certainty).
1 finding from 1 review
Number abstinent at completion of dose taper − Outpatient · Adults or adolescents with opioid dependence
It is very uncertain whether rapid changes number abstinent at completion of dose taper − Outpatient compared with slow taper of buprenorphine dose (very low certainty).
1 finding from 1 review
Completion of withdrawal treatment − Inpatient · Adults or adolescents with opioid dependence
Rapid showed no clear difference in completion of withdrawal treatment − Inpatient compared with slow taper of buprenorphine dose (low certainty).
1 finding from 1 review
Complete response · patients with high‐risk neuroblastoma
Rapid COJEC showed no clear difference in complete response compared with standard induction therapies (low certainty).
1 finding from 1 review
Early toxicities (during preoperative chemotherapy): febrile neutropenia (2 or more episodes), proven fungal infections, septicemia (1 or more episodes), gastrointestinal toxicity (grade 3 or 4), renal toxicity (glomerular filtration rate < 80 ml/... · patients with high‐risk neuroblastoma
1 finding from 1 review
Treatment‐related mortality · patients with high‐risk neuroblastoma
Rapid COJEC showed no clear difference in treatment‐related mortality compared with standard induction therapies (low certainty).
1 finding from 1 review
Overall survival · patients with high‐risk neuroblastoma
Rapid COJEC showed no clear difference in overall survival compared with standard induction therapies (low certainty).
1 finding from 1 review
Progression‐free survival ‐ not reported · patients with high‐risk neuroblastoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · patients with high‐risk neuroblastoma
Rapid COJEC showed no clear difference in event‐free survival compared with standard induction therapies (low certainty).
1 finding from 1 review
Late non‐hematological toxicities: any complication, renal toxicity (Glomerular Filtration Rate < 80 ml/min per body surface area of 1.73 m2), ototoxicity (Brock grade 1 to 4), endocrine complications (see table of included studies for included di... · patients with high‐risk neuroblastoma
1 finding from 1 review
All‐cause mortality · people with bloodstream infections
Rapid susceptibility methods showed no clear difference in mortality compared with standard methods versus placebo (low certainty).
1 finding from 1 review
Mortality (subgroup genotypic) · people with bloodstream infections
Rapid susceptibility methods showed no clear difference in mortality (subgroup genotypic) compared with standard methods versus placebo (low certainty).
1 finding from 1 review
Mortality (subgroup phenotypic) · people with bloodstream infections
Rapid susceptibility methods showed no clear difference in mortality (subgroup phenotypic) compared with standard methods versus placebo (low certainty).
1 finding from 1 review
Mortality (with stewardship) · people with bloodstream infections
Rapid susceptibility methods showed no clear difference in mortality (with stewardship) compared with standard methods versus placebo (low certainty).
1 finding from 1 review
Mortality (without stewardship) · people with bloodstream infections
Rapid susceptibility methods showed no clear difference in mortality (without stewardship) compared with standard methods versus placebo (low certainty).
1 finding from 1 review
Time to hospital discharge · people with bloodstream infections
1 finding from 1 review
Time‐to‐appropriate antibiotic · people with bloodstream infections
1 finding from 1 review
Mortality at 12 months · people living with HIV
It is very uncertain whether rapid antiretroviral therapy (ART) changes mortality at 12 months compared with standard care (very low certainty).
1 finding from 1 review